Presco Reports Q2 2017 Results; Sales Up by 30.4% YoY


Thursday, August 3, 2017 3:50PM/ FBNQuest Research

Event:                                   Presco reports Q2 2017 results

:                    Positive market reaction expected

                           Q2 2017 sales up 30.4% y/y, PBT up 10.1% y/y

                       Opex growth of 28% y/y came in higher than we expected; -N243m fx loss

Presco reported its Q2 2017 results this afternoon showing sales growth of 30.4% y/y to N5.7bn. Similarly, PBT and PAT increased by 10.1% y/y and 2.5% y/y respectively. The topline growth surprised slightly.

The company continued to benefit from increased demand following encouraging government policy on crude palm oil imports. This has also given it increased pricing power. The bottomline growth was significantly influenced by a gross margin expansion of 649bps y/y to 70.1%.

Added to it was a 15.8% y/y rise in biological asset revaluation gain to N469m. Both factors were large enough to offset the impact of a 28.4% y/y rise in opex, a -91.9% y/y reduction in other operating income, a 128.7% rise in net finance charges as well as a -N243m exchange rate loss. Tax expense was 27.3% higher y/y, resulting in the modest PAT growth.

When compared the company’s stellar Q1 2017 results, the quarterly trends showed declines. Sales fell by -21.2% q/q, while PBT and PAT were down by -49.0% q/q and -57.6% q/q respectively. 

With respect to the H1 figures, sales increased by 70.6% y/y to N12.8bn, PBT advanced by 84.1% y/y to N7.6bn while PAT increased by 84.4% y/y to N5.6bn.  

Responsible for the PBT growth were a 1,220bp y/y expansion in gross margin to 75.5% and a 67.5% y/y rise in biological assets revaluation gain to N1.1bn, despite a huge 185.0% y/y jump in opex to N2.5bn and a -N434m exchange rate loss. Income tax expense was 83.3% higher y/y. 

If we strip out the gains on biological asset revaluation and the fx loss, the underlying results reveal that Q2 PBT was flattish y/y while PAT was down -11.5% y/y.  

The H1 results were still up, although by a lower magnitude: PBT and PAT grew by 78.6% y/y and 76.9% y/y respectively. Comparing underlying results with our estimates, sales were 10.7% ahead while PBT and PAT missed by -5.1% and -14.8% respectively.  

On an annualised basis, H1 sales are in line with consensus’ FY sales estimate of N25.7bn. PBT and PAT are tracking ahead of consensus’ N12bn and N9bn estimates. 

Year-to-date, Presco shares have gained 85.8%, outperforming the NSEASI by 48.5%. We expect the market to react positively to these results initially but not aggressively given where the stock is currently trading at. We rate the stock Outperform.  

Our estimates are under review. 

Presco Q2 2017 results: actual vs. FBNQuest Research estimates (N millions) 

Related News
PRESCO Declares N3.90bn PAT in Q1'17 Result,(SP:N64.54k)
Presco Q4 2016 and Q1 2017 Results Review - Upgrading to Outperform
Presco Plc - Impressive Start to FY'17, Ahead of Estimates
Presco Q1 2017 Results – Operating Expenses Up by 120% YoY
PRESCO Declares N21.74bn PAT in Q4'16 Audited Result,(SP:N47.00k)
Positive Earnings Outlook in H2 2016 for Presco Plc
PRESCO Declares N3.01bn PAT in Q2 16 Result SP N38.85k
Presco s OPEX Up by 134 YoY in Q2 16 Results Shares Outperform the ASI


Related News